Linked Life Data

17628533

Source:http://linkedlifedata.com/resource/pubmed/id/17628533

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2007-8-20
pubmed:abstractText
Although probucol is known to prevent restenosis by regulating vascular remodeling after percutaneous transluminal coronary angioplasty, the mechanisms remain unclear. The present study was designed to investigate whether probucol mediates vascular remodeling via the extracellular signal-regulated kinase 1/2 (ERK1/2) signalling pathway. A rabbit restenosis model was used, in which the New Zealand white rabbits received angioplasty with a 3.5 F angioplasty balloon catheter and the proliferation and migration of smooth muscle cells (SMCs) was induced by oxidized low-density lipoprotein (ox-LDL). We evaluated several vascular remodeling parameters and found that probucol prevented lumen restenosis and mediated expansive remodeling with a remodeling index greater than 1 and that the proliferation and migration of SMCs was inhibited. Based on Western blot analyses, probucol decreased the expression of phospho-mitogen-activated protein kinase kinases 1 (p-MEK1) and phospho-ERK1/2 and enhanced the expression of mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) and caveolin-1. Cells treated with the MEK1 inhibitor PD98059 demonstrated a remarkable suppression of the effects of probucol. Furthermore, immunofluorescence analysis showed that probucol inhibited the activation of ERK1/2 by preventing its translocation to the nucleus. It was also found that c-myc expression in aortic tissue after angioplasty and the activator protein 1 (AP1) activity in SMCs induced by ox-LDL were decreased with probucol treatment. In conclusion, probucol mediated vascular remodeling to prevent restenosis after angioplasty by down-regulating the ERK1/2 signaling pathway.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0014-2999
pubmed:author
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
570
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-34
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:17628533-Angioplasty, Balloon, pubmed-meshheading:17628533-Animals, pubmed-meshheading:17628533-Antioxidants, pubmed-meshheading:17628533-Atherosclerosis, pubmed-meshheading:17628533-Caveolin 1, pubmed-meshheading:17628533-Cell Movement, pubmed-meshheading:17628533-Cell Proliferation, pubmed-meshheading:17628533-Cell Survival, pubmed-meshheading:17628533-Cells, Cultured, pubmed-meshheading:17628533-Coronary Restenosis, pubmed-meshheading:17628533-Down-Regulation, pubmed-meshheading:17628533-Dual Specificity Phosphatase 1, pubmed-meshheading:17628533-Genes, myc, pubmed-meshheading:17628533-Humans, pubmed-meshheading:17628533-Hyperplasia, pubmed-meshheading:17628533-MAP Kinase Kinase 1, pubmed-meshheading:17628533-Male, pubmed-meshheading:17628533-Mitogen-Activated Protein Kinase 1, pubmed-meshheading:17628533-Mitogen-Activated Protein Kinase 3, pubmed-meshheading:17628533-Muscle, Smooth, Vascular, pubmed-meshheading:17628533-Myocytes, Smooth Muscle, pubmed-meshheading:17628533-Probucol, pubmed-meshheading:17628533-Rabbits, pubmed-meshheading:17628533-Thoracic Arteries, pubmed-meshheading:17628533-Transcription Factor AP-1, pubmed-meshheading:17628533-Tunica Intima
pubmed:year
2007
pubmed:articleTitle
Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway.
pubmed:affiliation
Department of Pharmacology, School of Pharmaceutical Science, Central South University, Changsha 410078, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't